Large genetic study uncovers new Alzheimer’s drug targets

A major analysis of genetic data has linked 127 gene locations to Alzheimer’s disease, including 48 previously unidentified ones. Researchers also flagged several genes as promising drug targets and highlighted changes in immune and nerve cells.

The study examined genome information from nearly 110,000 people diagnosed with Alzheimer’s and 74,000 others who had a parent with the condition. It compared these against data from 2.6 million people without the disease. This effort identified 127 associated gene locations, 48 of which are new findings.

관련 기사

A team of researchers led by Professor Yan-Jiang Wang has published a review arguing that Alzheimer's disease requires integrated treatments targeting multiple factors, not single causes. New drugs like lecanemab and donanemab offer modest benefits by slowing decline, but fall short of reversal. The paper, in Science China Life Sciences, emphasizes genetics, aging, and systemic health alongside amyloid-beta and tau proteins.

AI에 의해 보고됨

Scientists at the University of Southern California have found experimental compounds that may reduce harmful brain inflammation associated with Alzheimer’s disease. The work focuses on the enzyme cPLA2 and people who carry the high-risk APOE4 gene.

Doug Whitney, a US mechanic carrying a genetic mutation that typically triggers early-onset Alzheimer’s disease, has reached his late 70s without symptoms. Researchers link his protection to decades of intense heat exposure in ship engine rooms. The case bolsters evidence that heat therapy may safeguard the brain against the condition.

AI에 의해 보고됨 사실 확인됨

Researchers from the Institute for Bioengineering of Catalonia and collaborating institutions report that engineered “supramolecular” nanoparticles restored aspects of blood-brain barrier function in Alzheimer’s-model mice, rapidly lowering brain amyloid-β and producing improvements on behavioral and memory tests.

이 웹사이트는 쿠키를 사용합니다

사이트를 개선하기 위해 분석을 위한 쿠키를 사용합니다. 자세한 내용은 개인정보 보호 정책을 읽으세요.
거부